65 related articles for article (PubMed ID: 12580991)
1. Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers.
Muscat JE; Pittman B; Kleinman W; Lazarus P; Stellman SD; Richie JP
Biochem Pharmacol; 2008 Oct; 76(7):929-37. PubMed ID: 18703023
[TBL] [Abstract][Full Text] [Related]
2. Association between caffeine metabolites in urine and muscle strength in young and older adults: A cross-sectional study from NHANES 2011-2012.
Batista-da-Silva B; Limirio LS; de Oliveira EP
Clin Nutr; 2024 May; 43(6):1584-1592. PubMed ID: 38759491
[TBL] [Abstract][Full Text] [Related]
3. PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.
McDonagh EM; Boukouvala S; Aklillu E; Hein DW; Altman RB; Klein TE
Pharmacogenet Genomics; 2014 Aug; 24(8):409-25. PubMed ID: 24892773
[No Abstract] [Full Text] [Related]
4. Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females.
Wenk M; Todesco L; Krähenbühl S
Br J Clin Pharmacol; 2004 Apr; 57(4):495-9. PubMed ID: 15025748
[TBL] [Abstract][Full Text] [Related]
5. The use of caffeine as a metabolic probe for human drug metabolizing enzymes.
Miners JO; Birkett DJ
Gen Pharmacol; 1996 Mar; 27(2):245-9. PubMed ID: 8919637
[TBL] [Abstract][Full Text] [Related]
6. Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug.
Vrtic F; Haefeli WE; Drewe J; Krähenbühl S; Wenk M
Br J Clin Pharmacol; 2003 Feb; 55(2):191-8. PubMed ID: 12580991
[TBL] [Abstract][Full Text] [Related]
7. Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities.
Fuchs P; Haefeli WE; Ledermann HR; Wenk M
Eur J Clin Pharmacol; 1999 Jan; 54(11):869-76. PubMed ID: 10027663
[TBL] [Abstract][Full Text] [Related]
8. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans.
Rasmussen BB; Brøsen K
Ther Drug Monit; 1996 Jun; 18(3):254-62. PubMed ID: 8738764
[TBL] [Abstract][Full Text] [Related]
9. Extractionless method for the simultaneous high-performance liquid chromatographic determination of urinary caffeine metabolites for N-acetyltransferase 2, cytochrome P450 1A2 and xanthine oxidase activity assessment.
Nyéki A; Biollaz J; Kesselring UW; Décosterd LA
J Chromatogr B Biomed Sci Appl; 2001 May; 755(1-2):73-84. PubMed ID: 11393735
[TBL] [Abstract][Full Text] [Related]
10. Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities.
Hakooz NM
Curr Drug Metab; 2009 May; 10(4):329-38. PubMed ID: 19519341
[TBL] [Abstract][Full Text] [Related]
11. Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?
Jetter A; Kinzig M; Rodamer M; Tomalik-Scharte D; Sörgel F; Fuhr U
Eur J Clin Pharmacol; 2009 Apr; 65(4):411-7. PubMed ID: 19082994
[TBL] [Abstract][Full Text] [Related]
12. Molecular aspects of renal anionic drug transport.
Russel FG; Masereeuw R; van Aubel RA
Annu Rev Physiol; 2002; 64():563-94. PubMed ID: 11826280
[TBL] [Abstract][Full Text] [Related]
13. Isolation of a family of organic anion transporters from human liver and kidney.
Sun W; Wu RR; van Poelje PD; Erion MD
Biochem Biophys Res Commun; 2001 May; 283(2):417-22. PubMed ID: 11327718
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
